Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline vs GnRH Antagonist Rescue + Cabergoline for OHSS Prevention
NCT02461875Phase 2Unknown
- Sponsor
- Al Jazeera Hospital
- Start
- May 2013
- Primary completion
- Nov 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of cetrorelix in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Al Jazeera Hospital. Primary endpoint: Moderate or severe ovarian hyperstimulation syndrome at 4 weeks. Status: unknown.
02
Drugs
cetrorelix
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT02461875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461875.